Yahoo Web Search

Search results

    • Q1 2024 Acumen Pharmaceuticals Inc Earnings Call

      Thomson Reuters StreetEvents via Yahoo Finance· 2 hours ago

      R&D expenses were $12.4 million in the first quarter. The increase over the prior year was primarily due to the increased spending to support the ALTITUDE-AD trial. G&A expenses ...

    • Q1 2024 Ocugen Inc Earnings Call

      Thomson Reuters StreetEvents via Yahoo Finance· 3 hours ago

      With the clinical updates expected in the third quarter of 2024. Our cell therapy platform is poised to advance that the renovations to our existing facility completed earlier this year. This ...

  1. Related searches

    esgr statement of support